<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/87AED907-EEFA-4677-BDB2-EAE1CFDC9F5A"><gtr:id>87AED907-EEFA-4677-BDB2-EAE1CFDC9F5A</gtr:id><gtr:name>University of Sao Paolo</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Medical Sciences Division</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/87AED907-EEFA-4677-BDB2-EAE1CFDC9F5A"><gtr:id>87AED907-EEFA-4677-BDB2-EAE1CFDC9F5A</gtr:id><gtr:name>University of Sao Paolo</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/98B55E8F-21B2-4A6A-9CE2-BB709FCDAD77"><gtr:id>98B55E8F-21B2-4A6A-9CE2-BB709FCDAD77</gtr:id><gtr:firstName>Andrew O M</gtr:firstName><gtr:surname>Wilkie</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601260"><gtr:id>4D918C83-B111-47C6-8E64-D144C0B45943</gtr:id><gtr:title>RAB23 mutations and insights into craniosynostosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601260</gtr:grantReference><gtr:abstractText>Growth of the skull occurs at the cranial sutures, which are seams of tissue that separate the skull bones. Early closure of the seams is termed craniosynostosis and may cause a variety of problems ? for example affecting vision, breathing, intelligence and psychological development. Although we know that craniosynostosis is sometimes caused by a misprint in a genetic instruction, many of these misprints remain unknown. 

Recently we identified a new gene, termed RAB23, that is altered in craniosynostosis. This was surprising because RAB23 belongs to a set of genetic instructions that were not previously thought to be involved in this condition. We hope to find out whether changes in related instructions also cause craniosynostosis or other malformations. We will use various methods in this research, including scanning genes in humans and mice for misprints, looking at how protein components stick to each other, and altering the instructions in bones isolated from mouse skulls.

By understanding more about how the skull normally develops and how craniosynostosis arises, we aim to develop new diagnostic tests, and hence provide patients and families with better information on the causes of these conditions and the chances that they could occur again in future children.</gtr:abstractText><gtr:technicalSummary>Craniosynostosis is an important human disease caused by the premature fusion of the sutures between the skull bones (birth prevalence 1 in 2,500). Severe cases are associated with multiple complications (physical, neurodevelopmental and psychological) requiring multidisciplinary management. An underlying genetic cause can currently be identified in about 25% of cases: this provides information that is fundamental for precise diagnosis, management and counselling. In the remaining 75%, the challenge is to distinguish those that also have an unidentified single gene aetiology from others with a more complex polygenic/environmental causation. 

We have recently discovered the gene that is mutated in Carpenter syndrome, a rare recessive disorder comprising complex craniosynostosis, polysyndactyly, obesity, cardiac defects and learning difficulties. Unexpectedly the gene encodes RAB23, a negative regulator of signalling by hedgehog proteins, which are involved in the development of many organs but have not previously been implicated in craniosynostosis. 

This project will explore the contribution of RAB23 mutations to disease, and of hedgehog signalling proteins to craniosynostosis. First, we aim to understand the mutation spectrum in RAB23 itself. To date we have analysed 11 unrelated mutation positive families but only identified 4 distinct mutations, probably owing to founder effects. We will recruit and analyse additional Carpenter syndrome patients, especially those from different ethnic backgrounds. We will test the effects of different mutations on nonsense-mediated decay in patient cells and artificial constructs, and explore genotype/phenotype correlations in RAB23 mutation by analysing patients with acrocallosal syndrome, a possibly allelic condition, and seeking additional murine Rab23 mutations in an ethylnitrosourea mutagenesis screen. This information will assist transfer of this work into the clinical molecular diagnostic laboratory, which should be achieved by the end of year 1. Next we will screen additional candidate genes in the hedgehog pathway for mutations in a large panel of DNA samples from patients with undiagnosed craniosynostosis and/or limb malformations. We will focus on the best candidates which are (1) Indian hedgehog, the ligand expressed in cranial sutures; (2) genes that, like Rab23, exhibit activation of hedgehog signalling in mouse mutants; and (3) genes encoding proteins that interact directly with Rab23, which we will identify by a combination of yeast 2-hybrid and proteomics-based screening. Finally, we will manipulate Rab23 activity in an in vitro culture of murine cranial sutures using morpholino knockdown, and monitor the effects of this on morphology and expression of genes implicated in hedgehog signalling and craniosynostosis.</gtr:technicalSummary><gtr:fund><gtr:end>2010-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>342370</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sao Paulo</gtr:collaboratingOrganisation><gtr:country>Brazil, Federative Republic of</gtr:country><gtr:description>Genetic basis of Carpenter syndrome</gtr:description><gtr:id>D493E170-8913-42F5-A383-52D3A99C49BA</gtr:id><gtr:impact>PMID: 17503333</gtr:impact><gtr:outcomeId>F9CF380AEC0-1</gtr:outcomeId><gtr:partnerContribution>Provision of patient samples</gtr:partnerContribution><gtr:piContribution>Identified mutations of RAB23 in patients, documenting genetic heterogeneity</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>116875</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grants</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Newlife</gtr:fundingOrg><gtr:fundingRef>10-11/04</gtr:fundingRef><gtr:id>44EA0B2B-5AB1-4408-80ED-981239D7989C</gtr:id><gtr:outcomeId>BZ3kxAYDaVG</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Proposal form for the evaluation of a genetic test for NHS service (Gene Dossier)</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>61BB297C-1438-480A-BF31-6449491CFD86</gtr:id><gtr:impact>Introduction of RAB23 as an accredited genetic test in NHS diagnostic laboratory (Oxford). Enables accurate genetic diagnosis, genetic counselling and prenatal testing for Carpenter syndrome for the first time.</gtr:impact><gtr:outcomeId>oja4DgUMa82</gtr:outcomeId><gtr:type>Citation in other policy documents</gtr:type><gtr:url>http://ukgtn.nhs.uk/uploads/tx_ukgtn/Carpenter_syndrome_RAB23_GD_Sept_10.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>This diagnostic tool has been approved for clinical use by the UK Genetic Testing Network and has been implemented in the Oxford NHS Genetics laboratory.</gtr:description><gtr:id>78C85F4E-10E2-4D59-8147-CC49C5419D87</gtr:id><gtr:impact>Both clinical and prenatal diagnoses have been performed.</gtr:impact><gtr:outcomeId>focCSqJ6WU3</gtr:outcomeId><gtr:stage>Small-scale adoption</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>Molecular genetic analysis of RAB23 gene for diagnosis of Carpenter syndrome</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>6E95AAE9-CFB7-43BD-B117-F5587C91DF2A</gtr:id><gtr:title>Metopic and sagittal synostosis in Greig cephalopolysyndactyly syndrome: five cases with intragenic mutations or complete deletions of GLI3.</gtr:title><gtr:parentPublicationTitle>European journal of human genetics : EJHG</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4bb96ff0ca5b0e436b765094c1b2ea10"><gtr:id>4bb96ff0ca5b0e436b765094c1b2ea10</gtr:id><gtr:otherNames>Hurst JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1018-4813</gtr:issn><gtr:outcomeId>RWjVXKpSHDB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C9663CF-A584-4FB8-AE19-CA28DD46331E</gtr:id><gtr:title>Mutations in multidomain protein MEGF8 identify a Carpenter syndrome subtype associated with defective lateralization.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d72dd3d808c0e61e97ae41b202875ea9"><gtr:id>d72dd3d808c0e61e97ae41b202875ea9</gtr:id><gtr:otherNames>Twigg SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>pm_15242_22_23063620</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC192F45-3114-4350-AF09-135AB389F23F</gtr:id><gtr:title>Carpenter syndrome: extended RAB23 mutation spectrum and analysis of nonsense-mediated mRNA decay.</gtr:title><gtr:parentPublicationTitle>Human mutation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8bcf13d3c38170a51d13b768c6b58fb3"><gtr:id>8bcf13d3c38170a51d13b768c6b58fb3</gtr:id><gtr:otherNames>Jenkins D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1059-7794</gtr:issn><gtr:outcomeId>Sj9PQMYEdJ8</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601260</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>78FE8F42-8AFB-48F8-8662-37D541AD95BF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Congenital Disorders</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>